English | Español

China Food And Drug Administration
Robert Hadley | May 14, 2017

Bristol-Myers Squibb dual-drug treatment for hepatitis C gains China approval
Gene Johnson | Mar 24, 2017

China approves Xeljanz to treat moderate to severe rheumatoid arthritis

Trending
+ Regulatory
C.D. Marsden | Apr 12, 2025

Empower Pharmacy: Eli Lilly lawsuit is ‘Big Pharma’s attempt to limit patient and provider choice’
+ Pharmaceuticals
Patient Daily | Apr 15, 2025

UCSF neurosurgeon: '340B is a drug discount program that hospitals exploit as an additional revenue stream'
+ Pharmaceuticals
Patient Daily | Apr 15, 2025

President of Drug Channels Institute: 'Hospital prices are significantly higher at large 340B hospitals'
+ Pharmaceuticals
Patient Daily | Apr 15, 2025

Former Domestic Policy Council director: 340B program turns large non-profit hospitals into 'pure profit' centers